The ADRIATIC trial evaluated the efficacy of durvalumab as consolidation therapy following concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer (LS-SCLC). The study demonstrated that durvalumab significantly improved both progression-free survival (PFS) and overall survival (OS) compared to placebo.
Patients receiving durvalumab showed a median PFS of 16.6 months versus 9.2 months with placebo. The median OS was 55.9 months for the durvalumab group compared to 33.4 months for the placebo group. The hazard ratios favored durvalumab for both PFS and OS with statistical significance, indicating a substantial survival benefit.
The safety profile of durvalumab was consistent with previous studies, with manageable adverse events. These findings support the use of durvalumab as a consolidation therapy in LS-SCLC, offering a new standard of care in this setting.
